Brought to you by 
Chroma, GSK collaborate on anti-inflammatory small molecules
01 Feb 2013
Executive Summary
Chroma Therapeutics (small-molecule drug discovery targeting chromatin-modifying enzymes) has agreed to partner four small-molecule programs in inflammation with GlaxoSmithKline's Center of Excellence for External Drug Discovery.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Chroma, GSK collaborate on anti-inflammatory small molecules
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice